Walthausen & Co’s iRadimed IRMD Stock Holding History

Walthausen & Co’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-17,310	Closed	-$643K	–	140
2018 Q3	$643K	Buy	+17,310	New	+$467K	0.06%	134

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return

CCM

Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Walthausen & Co's IRMD Position: Q4 2018 in Review

Walthausen & Co sold out of iRadimed (IRMD) in Q4 2018, closing a stake of 17,310 shares — an estimated $643K sold.

Walthausen & Co first reported a position in IRMD in Q3 2018 and held it in 1 quarter. The position peaked at $643K in Q3 2018. 67 funds tracked by Wall St. Rank hold IRMD as of Q4 2018.

Walthausen & Co reported no remaining iRadimed position as of Q4 2018 after selling out during the quarter.
Walthausen & Co sold 17,310 iRadimed shares in Q4 2018, an estimated $643K.
Walthausen & Co first reported a position in iRadimed in Q3 2018 and held it in 1 quarter.
Walthausen & Co's iRadimed position peaked at $643K in Q3 2018.
67 funds tracked by Wall St. Rank held iRadimed as of Q4 2018.

Based on Walthausen & Co's 13F filing for Q4 2018, filed 22 Feb 2019.